Latest news and press releases about Sana Biotechnology, Inc. (SANA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses.
Price
| Price | $2.92 |
| Market Cap | $813M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.00 |
| EV / EBITDA | -4.36 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -134.49% |
| Return on Invested Capital | -64.54% |
| Return on Assets | -49.09% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: DNTH · INBX · KOD · NKTR · NRIX · OCS · PHAT
Explore sector: Healthcare · Biotechnology
More sections of SANA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks